Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 29Prostate Adenocarcinoma 3Stage I Prostate Adenocarcinoma AJCC v7 1PSA Level Greater Than Two 1Neoplasms 1Neoplasm Metastasis 1Castration-resistant Prostate Cancer Patients with Oligometastases 1Adenocarcinoma 1

Interventions

Radiosurgery 79Capecitabine 77Oxaliplatin 74Fluorouracil 69Bevacizumab 69Gemcitabine 67Leucovorin 61pembrolizumab 53Nivolumab 53Paclitaxel 48Irinotecan 47Radiotherapy 45Cisplatin 44Everolimus 38Magnetic Resonance Spectroscopy 36Drug Therapy 36Docetaxel 36Cyclophosphamide 35Cetuximab 35Ipilimumab 32Carboplatin 32Trastuzumab 31Sunitinib 30Sorafenib 26Erlotinib Hydrochloride 25Doxorubicin 23Surveys and Questionnaires 20Surgical Procedures, Operative 20Specimen Handling 20Biopsy 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm Metastasis × luprolide acetate gel depot × Clear all
NCT01442246 2024-09-19

Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

UNICANCER

Phase 3 Active not recruiting
700 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡